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CORRESPONDENCE
Letter to the Editor
Dear Sir,
We have read Smith’s article on oxcarbazepine
(Seizure 2001; 10: 87–91) with great interest. In
almost all aspects, the recommendations for its use
closely correspond to our own practice and clinical
experience.
Regarding the overnight switch from carbamazepine
to oxcarbazepine, however, our experience differs in
two aspects. Smith and coworkers advise to switch
only patients on oxcarbazepine monotherapy in a
single step, and they regard only patients on a
maximum daily dosage of 800 mg carbamazepine as
good candidates for an overnight switch.
We have recently evaluated the overnight switch of
more than 50 patients from carbamazepine to oxcar-
bazepine. 74% of patients were under polytherapy, and
the mean carbamazepine dosage before switching was
1340 mg/die (range 400–2400 mg/die). Side effects
like transient dizziness, blurred vision, and tiredness
occurred in 29% of patients, including 2 rashes. In
the majority of these patients, CNS toxicity was mild
and remitted spontaneously within a few days. There
was a trend towards higher dosages of oxcarbazepine
(mean 2000 mg/die, range 450–3300 mg/die) in
patients experiencing side effects. However, the mean
initial oxcarbazepine dosage in patients without
any side effects related to the overnight switch
was 1654 mg/die corresponding to a mean prior
carbamazepine dosage of about 1200 mg/die.
Thus, in our hands a rapid switch from car-
bamazepine to oxcarbazepine was generally well
tolerated at higher initial dosages and also in patients
treated in combination with one or two additional
anticonvulsive drugs despite an increase in the serum
levels of their co-medication.
A rapid switch offers advantages over a slow
titration by avoiding an instable transition period, and
it often improves seizure control (in our series with
a mean reduction in seizure frequency by more than
60%). Therefore we suggest that an overnight switch
should also be taken into consideration in patients
treated under polytherapy, and with higher dosages of
carbamazepine.
Yours sincerely,
A. Schulze-Bonhage and V. Homberg
Epilepsy Centre
University of Freiburg
Germany
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